BeyondSpring Inc. (BYSI): Capital Expenditures
$50.0K
Year ended 2025-12-31
$0
Trailing 12 months to 2026-06-30
+13.7%
3-year compound annual growth
-0.8%
5-year compound annual growth
+2.3%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $50.0K | -77.7% | 2026-03-25, From 2025-01-01 |
| 2024-12-31 | $224.0K | +124.0% | 2026-03-25, From 2024-01-01 |
| 2023-12-31 | $100.0K | +194.1% | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | $34.0K | -98.8% | 2023-04-18, From 2022-01-01 |
| 2021-12-31 | $2.84M | n/m | 2023-04-18, From 2021-01-01 |
| 2020-12-31 | $52.0K | n/m | 2023-04-18, From 2020-01-01 |
| 2019-12-31 | $4.0K | -98.1% | 2022-04-14, From 2019-01-01 |
| 2018-12-31 | $207.0K | +172.4% | 2021-04-30, From 2018-01-01 |
| 2017-12-31 | $76.0K | +18.8% | 2020-04-30, From 2017-01-01 |
| 2016-12-31 | $64.0K | +60.0% | 2019-04-30, From 2016-01-01 |
| 2015-12-31 | $40.0K | n/a | 2018-04-03, From 2015-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| BeyondSpring Inc. (BYSI) | 2025-12-31 | $50.0K | -77.7% |
| Abbott Laboratories (ABT) | 2025-12-31 | $2.17B | -1.6% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $1.31B | +5.0% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $7.84B | +55.0% |
| Pfizer Inc (PFE) | 2025-12-31 | $2.63B | -9.6% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $4.83B | +9.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $6.48M | -40.9% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $4.11B | +21.9% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $28.0K | n/a |
Compare BYSI, ABT, BMY, LLY side by side · Screen every company in Pharmaceutical Preparations ↗